Linden Sp. z o.o. sp.k.
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The centre is conducting studies on cardiovascular diseases such as acute myocardial infarction, heart failure and hypertension, aiming to test new therapies that lower the risk of major cardiac events.
- Acute myocardial infarction
- Heart failure with preserved ejection fraction
- Hypertension
- Atherosclerotic cardiovascular disease
- Elevated lipoprotein(a)
Trials at Linden Sp. z o.o. sp.k. focus on reducing cardiovascular mortality, improving functional capacity and evaluating the safety of novel agents.
Neurological Disorders
Research in neurological disorders includes amyotrophic lateral sclerosis, Parkinson's disease and various headache conditions, with objectives to slow disease progression and relieve symptoms.
- Amyotrophic Lateral Sclerosis (ALS)
- Parkinson's disease
- Migraine (episodic and chronic)
- Traumatic brain injury (subacute moderate to severe)
- Insomnia disorder
- Narcolepsy with cataplexy (type 1)
The studies aim to evaluate disease‑modifying agents, novel pain‑relief strategies and sleep‑improving treatments while monitoring long‑term safety.
Metabolic and Nutritional Diseases
The site is exploring therapies for metabolic and nutritional diseases such as obesity, type 2 diabetes and related bone health concerns, seeking to improve metabolic control and weight outcomes.
- Overweight and obesity with type 2 diabetes
- Type 2 diabetes mellitus
- Weight reduction interventions
- Bone mineral density in women using hormonal contraception
- Metabolic syndrome components
Trials evaluate agents like oral semaglutide and CagriSema to enhance glycaemic control, promote weight loss and support skeletal health.
Respiratory and Allergy Research
Investigations into respiratory and allergic conditions target asthma, allergic rhinoconjunctivitis and interstitial lung disease, with the goal of improving lung function and symptom relief.
- Asthma
- Allergic rhinoconjunctivitis caused by pollen exposure
- Interstitial lung disease (ILD)
- Chronic obstructive pulmonary disease (COPD) (exploratory)
Studies compare inhaled corticosteroid/long‑acting β‑agonist combinations and pollen‑extract immunotherapies to standard care, assessing efficacy and safety.
Musculoskeletal and Pain Management
The centre focuses on musculoskeletal and pain conditions, evaluating novel analgesics and spasticity treatments to enhance patient quality of life.
- Chronic non‑specific low back pain
- Post‑surgical neuropathic pain
- Upper‑limb spasticity after stroke or TBI
- Musculoskeletal physiological phenomena
- Osteoarthritis (investigational)
Research aims to determine optimal dosing of pain‑relieving agents, evaluate botulinum toxin for spasticity and assess functional outcomes.
Immunology and Autoimmune Diseases
Studies address immune‑mediated and autoimmune diseases such as systemic sclerosis and chronic inflammatory demyelinating polyneuropathy, testing biologics for disease control.
- Systemic sclerosis (limited and diffuse cutaneous subsets)
- Chronic inflammatory demyelinating polyneuropathy (CIDP)
- General autoimmune diseases
- Skin and connective tissue diseases
- Immune system disorders
The trials compare agents like anifrolumab and other targeted therapies to standard treatments, focusing on safety, efficacy and patient‑reported outcomes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 15 therapeutic areas and 15 of 48 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 25 by active trials.
- 1Zenas Biopharma (USA) LLC2active
lock +24 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novo Nordisk A/S5trials
lock +5 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Linden Sp. z o.o. sp.k.
lock Showing 1 of 45 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A MULTICENTER, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE EFFECTS OF TASIMELTEON VS. PLACEBO IN TREATING PEDIATRIC INSOMNIA | Vanda Pharmaceuticals Inc., Vanda Pharmaceuticals Netherlands B.V. | Phase III | Recruiting | Feb 2026 | — |
IMP list
lock Showing 1 of 48 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Semaglutide | 4 | Unknown | 2021-05-17 | 2026-05-27 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.